Bone metabolic effects of single-dose zoledronate in healthy dogs

Journal of Veterinary Internal Medicine

Volumn 19, Issue 6, 2005, Pages 924-927

  De Lorimier, Louis Philippe ^a   Fan, Timothy M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Alkaline phosphatase; Bone resorption; Cancer; Canine; Urine N telopeptide of type I collagen; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ANIMAL; ARTICLE; BLOOD; BONE; CLINICAL TRIAL; DOG; DRUG EFFECT; HEALTH; MALE; METABOLISM; TIME;

ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOGS; HEALTH; IMIDAZOLES; MALE; TIME FACTORS;

ANIMALIA; CANIS FAMILIARIS;

EID: 28444496693     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2005)19[924:BMEOSZ]2.0.CO;2     Document Type: Article

References (25)

1. Milner RJ, Farese J, Henry CJ, et al. Bisphosphonates and cancer. J Vet Intern Med 2004;18:597-604.
2. Thériault R. Zoledronic acid (Zometa®) use in bone disease. Expert Rev Anticancer Ther 2003;3:157-165.
3. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-2978.
4. Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program. Semin Oncol 2001;28(Suppl 6):17-24.
5. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-1236.
6. Berenson JR, Rosen LA, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-1200.
7. Body JJ. Current and future directions in medical therapy: Hypercalcemia. Cancer 2000;88:3054-3058.
8. Orcel P, Beaudreuil J. Bisphosphonates in bone diseases other than osteoporosis. Joint Bone Spine 2002;69:19-27.
9. Mönkkönen H, Lehenkari PP, Kellinsalmi M, et al. A new mechanism of action for bisphosphonates: Apppi dedicated cytotoxicity of N-BPs. Bone 2004;34:S66-S67.
10. Poirier VJ, Huelsmeyer MK, Kurzman ID, et al. The bisphosphonates alendronate and zoledronate are inhibitors of canine and human osteosarcoma cell growth in vitro. Vet Comp Oncol 2003;1:207-215.
11. Green JR. Antitumor effects of bisphosphonates. Cancer 2003; 97(Suppl 3):840-847.
12. Gordon S, Helfrich MH, Sati HI, et al. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 2002;119:475-483.
13. Dieli F, Gebbia N, Poccia F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003;102:2310-2311.
14. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-2026.
15. Rosen HN, Moses AC, Garber J, et al. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 1998;63:363-368.
16. Vinholes J, Guo CY, Purohit OP, et al. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997;15:131-138.
17. Vinholes J, Guo CY, Purohit OP, et al. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996;73:1089-1095.
18. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-1172.
19. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-289.
20. Allen MJ, Allen LC, Hoffmann WE, et al. Urinary markers of type I collagen degradation in the dog. Res Vet Sci 2000;69:123-127.
21. Allen LC, Allen MJ, Breur GJ, et al. A comparison of two techniques for the determination of serum bone-specific alkaline phosphatase activity in dogs. Res Vet Sci 2000;68:231-235.
22. Rumbeiha QK, Kruger JM, Fitzgerald SF, et al. Use of pamidronate to reverse vitamin D3-induced toxicosis in dogs. Am J Vet Res 1999;60:1092-1097.
23. Fan TM, de Lorimier LP, Charney SC, Hintermeister JG. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med 2005;19:74-80.
24. Allen MJ, Hoffmann WE, Richardson DC, Breur GJ. Serum markers of bone metabolism in dogs. Am J Vet Res 1998;59:250-254.
25. Rosol TJ, Chew DJ, Nagode LA, Schenck P. Disorders of calcium - Hypercalcemia and hypocalcemia. In: DiBartola SP, ed. Fluid Therapy in Small Animal Practice, 2nd ed. Philadelphia, PA: WB Saunders; 2000:108-162.